CN101198329A - 普拉格雷给药方案 - Google Patents

普拉格雷给药方案 Download PDF

Info

Publication number
CN101198329A
CN101198329A CNA2006800217943A CN200680021794A CN101198329A CN 101198329 A CN101198329 A CN 101198329A CN A2006800217943 A CNA2006800217943 A CN A2006800217943A CN 200680021794 A CN200680021794 A CN 200680021794A CN 101198329 A CN101198329 A CN 101198329A
Authority
CN
China
Prior art keywords
prasugrel
formula
dose
equivalent
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800217943A
Other languages
English (en)
Chinese (zh)
Inventor
J·T·勃兰特
N·A·法里德
J·A·雅库博夫斯基
C·D·佩恩
G·J·维拉科迪
K·J·温特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101198329A publication Critical patent/CN101198329A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA2006800217943A 2005-06-17 2006-06-13 普拉格雷给药方案 Pending CN101198329A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17
US60/691,740 2005-06-17

Publications (1)

Publication Number Publication Date
CN101198329A true CN101198329A (zh) 2008-06-11

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800217943A Pending CN101198329A (zh) 2005-06-17 2006-06-13 普拉格雷给药方案

Country Status (18)

Country Link
US (1) US20090156632A1 (enExample)
EP (1) EP1893205A4 (enExample)
JP (1) JP2008543853A (enExample)
KR (1) KR20080016647A (enExample)
CN (1) CN101198329A (enExample)
AU (1) AU2006259538A1 (enExample)
BR (1) BRPI0612624A2 (enExample)
CA (1) CA2612315A1 (enExample)
EA (1) EA200800075A1 (enExample)
EC (1) ECSP078014A (enExample)
GT (1) GT200600263A (enExample)
IL (1) IL187486A0 (enExample)
MA (1) MA29722B1 (enExample)
MX (1) MX2007015430A (enExample)
NO (1) NO20080244L (enExample)
TN (1) TNSN07474A1 (enExample)
WO (1) WO2006138317A2 (enExample)
ZA (1) ZA200710769B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100610A4 (en) 2006-12-07 2009-12-02 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
KR20030014294A (ko) * 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
PL206138B1 (pl) * 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物

Also Published As

Publication number Publication date
EP1893205A4 (en) 2010-06-30
MA29722B1 (fr) 2008-09-01
TNSN07474A1 (en) 2009-03-17
EA200800075A1 (ru) 2008-04-28
NO20080244L (no) 2008-01-14
CA2612315A1 (en) 2006-12-28
JP2008543853A (ja) 2008-12-04
ECSP078014A (es) 2008-01-23
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
ZA200710769B (en) 2009-09-30
KR20080016647A (ko) 2008-02-21
WO2006138317A3 (en) 2007-05-03
WO2006138317A2 (en) 2006-12-28
EP1893205A2 (en) 2008-03-05
US20090156632A1 (en) 2009-06-18
GT200600263A (es) 2007-02-23
IL187486A0 (en) 2008-06-05
BRPI0612624A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
US8569325B2 (en) Method of treatment with coadministration of aspirin and prasugrel
US8623826B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
EP2722044B1 (en) Compositions for treating centrally mediated nausea and vomiting
AU2013205648B2 (en) Combination treatment
JP6657420B2 (ja) クロピドグレル及びアスピリンを含む複合製剤
US20080214599A1 (en) Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
EA034956B1 (ru) Способ для лечения язвенного колита
CN102036669B (zh) 用于治疗早泄的药物组合物
CN102149377A (zh) 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途
CN101198329A (zh) 普拉格雷给药方案
KR20210031922A (ko) 간 질환의 가려움 증상 치료
US20200030319A1 (en) Dosing Regimens for Fast Onset of Antidepressant Effect
WO2009143662A1 (zh) 含钙通道阻滞剂和b族维生素的药物组合物及其用途
US20140051730A1 (en) Therapeutic use of dimiracetam to prevent the hand and foot syndrome caused by sorafenib
WO2011052500A1 (ja) ワックス安定製剤
WO2011052499A1 (ja) 貯蔵安定性が改善された医薬組成物
WO2014056418A1 (zh) 含有阿斯匹林和维卡格雷的药用组合物
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
HK1056118B (en) Medicinal compositions containing aspirin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080611